May 26, 2020 / 6:48 AM / 2 months ago

BRIEF-Astrazeneca Collaborates With Archerdx In Late-Stage Lung Cancer Trial

May 26 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA COLLABORATES WITH ARCHERDX TO USE PERSONALISED CANCER ASSAYS TO DETECT MINIMAL RESIDUAL DISEASE IN LUNG CANCER TRIALS

* ASTRAZENECA - ARCHERDX’S PERSONALISED ASSAY WILL BE USED IN ASTRAZENECA’S RECENTLY LAUNCHED PHASE III MERMAID-1 TRIAL

* ASTRAZENECA - ARCHERDX WILL PERFORM WHOLE EXOME SEQUENCING OF NSCLC PATIENT SAMPLES AND GENERATE HIGHLY SENSITIVE, PERSONALISED CTDNA ASSAYS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below